Gossec, Laure http://orcid.org/0000-0002-4528-310X
Humphries, Brittany
Rutherford, Megan
Taieb, Vanessa
Willems, Damon
Tillett, William http://orcid.org/0000-0001-7531-4125
Funding for this research was provided by:
UCB Pharma
Article History
Received: 4 May 2023
Accepted: 30 January 2024
First Online: 15 February 2024
Declarations
:
: This SLR and meta-analysis was based on published literature and de-identified results of the BE OPTIMAL (NCT03895203) trial [CitationRef removed]; therefore, additional ethics approval was not required. This paper was developed in accordance with the Good Publication Practice (GPP3) guidelines (ExternalRef removed).
: All authors agreed to the publication of this manuscript.
: LG: Received grants or contracts from Pfizer, Sandoz and UCB, consulting fees from AbbVie, Bristol-Myers Squibb, Celltrion, Galapagos, Janssen, Novartis, Pfizer and UCB, honoraria for lectures from AbbVie, Amgen, Galapagos, Gilead, Janssen, Lilly, MSD, Novartis, Pfizer, Sandoz and UCB, support for attending meetings and/or travel from MSD, Novartis, and Viatris, and has received medical writing support from AbbVie, Janssen, Pfizer and UCB. All unrelated to the present study. BH: Consultant to UCB Pharma. MR: Consultant to UCB Pharma. VT: Employee of UCB Pharma. DW: Employee and shareholder of UCB. WT: Research funding, consulting or speaker fees from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Pfizer and UCB. Consulting and speaker fees from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, MSD, Novartis, ONO Pharma, Pfizer and UCB.